New EVT801 presentation:"Kazia provides EVT801progress update
Dear Shareholder,
We wanted to share with you a newpresentation detailing Kazia’s EVT801 asset and the latest in its clinicaldevelopment program."
https://www.kaziatherapeutics.com/site/pdf/5c0efa93-b5cc-4d0d-9bcd-c9de9b65067f/EVT801-Progress-Update-Presentation.pdf
"To date, 32 patients have been included in the study, with 26 patients treated and 5 dosing cohorts completed up to 400mg, twice daily. The study investigators are actively enrolling patients in the 500mg, twice daily cohort.
A number of patients have remained on treatment for two or more cycles with 7 reaching cycle 3 (one reaching Cycle 9).
Biomarkers have shown strong VEGFR3 expression in some indications, and we have observed encouraging clinical activity in high grade serious ovarian cancer patients (strongly expressing VEGFR3). The Stage 1 Clinical and Biomarker update has been accepted for presentation at AACR 2024, which is being held from April 5-10, San Diego, California."
